30 results about "Enteric-coated granules" patented technology

The present invention relates to an enteric coated granule prepared by coating lactic acid bacteria-containing seed with a water-miscilble coating material and then, if desired, subjecting the first coated product to the second coating with a controlled-release coating material.

The invention relates to an oral preparation containing andrographolide and a preparation method thereof, belonging to the field of medicines. The oral preparation containing andrographolide is in dosage forms of enteric-coated granules, enteric-coated tablets, enteric-coated capsules and enteric-coated dispersible tablets which are prepared by mixing andrographolide and pharmaceutically acceptable auxiliary materials. The prepared oral preparation can reduce incidence of adverse reactions and side effects thereof and improve the medication safety while ensuring the therapeutic effect, and uses the andrographolide more widely.

The invention provides a granulating and coating process of esomeprazole magnesium contained in esomeprazole magnesium enteric-coated tablets. The granulating and coating process comprises the following steps of: firstly preparing esomeprazole magnesium granules; then preparing esomeprazole magnesium enteric-coated granules sequentially through isolating layer coating and enteric-coated layer coating; and finally blending adjuvants with the esomeprazole magnesium enteric-coated granules and tabletting to prepare the esomeprazole magnesium enteric-coated tablets. An appropriate granulating method comprises the following steps of: crushing and grinding the esomeprazole magnesium and the adjuvants into powder, and then uniformly mixing; mixing with an adhesive to obtain a water solution, stirring for 8-10 minutes in a wet type granulator to prepare appropriate granules; drying at 40-45 DEG C, and screening to obtain the granules with grain size being between 40 meshes and 80 meshes. According to the process including granulating and coating of raw materials, the enteric-coated granules are prepared firstly and then blended with the adjuvants and finally tabletting is carried out, pellets are not used, the content uniformity of the prepared esomeprazole magnesium enteric-coated tablet product is greatly enhanced, and the problem of unqualified uniformity of the product content caused by excessive material flowability in an original process is solved.

The present invention deals with a multiparticulate tablet, which disintegrates in the mouth containing: i) a proton pump inhibiting agent, in particular of the benzimidazole type, in the form of enteric coated microgranules, which enteric coated granules are overcoated with at least one barrier coating, such as for instance a methacrylic copolymer-based protective film; ii) at least one antacid in the form of granules, for instance based on CaCO3 and/or Mg(OH)2 and/or Al(OH)3; and, iii) a mixture of excipients comprising at least one disintegrating agent, one diluent agent, a lubricant, and optionally a swelling agent, a permeabilising agent, sweeteners, flavourings and colours. Furthermore, the present invention is directed to processes for the manufacture of the tablet and its use in the treatment of gastrointestinal disorders.

The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated granule comprising an intimate mixture of an aspirin active ingredient and at least one binder capable of preferentially absorbing ambient moisture.

The present invention is an enteric coated granule having controlled dissolution in water even at a small coating amount; and a preparation method thereof. More specifically, provided are an enteric coated granule comprising a raw granule or a granule comprising a raw granule and at least one layer covering the raw granule, a first enteric layer covering the raw granule or the granule, and a second enteric layer formed over the first enteric layer, wherein the first and the second enteric layers comprise a first and a second hydroxypropylmethyl cellulose acetate succinates (HPMCASs) different in solubility pH, respectively, and the solubility pH value of the second HPMCAS of the second enteric layer is lower than that of the first enteric layer; and a preparation method comprising steps of covering a raw granule or a granule comprising a raw granule and at least one layer covering the raw granule with an enteric coating agent comprising a first HPMCAS to form a first enteric layer; and forming, over the first enteric layer, a second coating layer by using a second enteric coating agent comprising a second HPMCAS having a lower solubility pH value than that of the first HPMCAS.

The invention discloses high-density dimethyl fumarate enteric-coated granules and a preparation method thereof. The density of the high-density dimethyl fumarate enteric-coated granules is 1.0g/mL or higher, or is 1.3g/mL or higher, or is 1.6g/mL or higher. Preparation size of the high-density dimethyl fumarate enteric-coated granules is small; the high-density dimethyl fumarate enteric-coated granules are convenient for administration, and are especially suitable for patients, elders, and children with swallowing difficulty, and are capable of increasing patient compliance; preparation content uniformity is high; rapid release is realized; stability is high; and the preparation method is simple, and is suitable for industrialized production.

The invention provides a melbine/acarbose hypoglycemic oral preparation composition and a preparation thereof. The weight ratio of the melbine to the acarbose comprised in the composition is 5:4 to 20:1, preferably, 5:2 to 10:1. Except the main medicaments, the composition also can further comprise normal medicament auxiliary materials, such as an adhesive, a filling agent, a disintegrating agent, a lubricating agent, a flavoring agent, a wetting agent and a glidant. The prepared composition can be prepared into tablets, granules, soft and hard capsules and sustained-release preparations by the common method, preferably enteric-coated tablets, enteric-coated granules and enteric-coated soft and hard capsules. The composition of the invention has the advantages of complementarity of action mechanisms of the main medicaments, multiple target points, good patient compliance and the like. The hypoglycemic oral preparation composition can be used for first-line treatment of type 2 diabetes, or can be used for second-line therapy under the the condition that a melbine or sulfonylurea medicament cannot singly and effectively control the blood sugar, and also can be used for the interferential treatment of impaired glucose tolerance.

The invention relates to an enteric coated granule of beta-mannase, a preparation method and application thereof in the feed industry. The invention improves the stability of the beta-mannase through carrying out enteric coated treatment on the beta-mannase, reduces the influence of physiological environment of animals on the enzyme activity and is beneficial to improving the application effect of the beta-mannase in feeds.

The invention discloses a lycopene-SOD (Superoxide Dismutase) enteric capsule and a preparation method thereof. The preparation method is characterized by comprising the following steps: grinding 5wt% of lycopene oil resin into lycopene beta-CD molecular inclusion complex in the presence of beta-CD which is 20 times as much as lycopene oil resin; then preparing lycopene beta-CD molecular inclusion complex into 40-mesh granules; coating the lycopene beta-CD molecular inclusion complex granules with enteric-soluble coated premix auxiliary materials to obtain enteric coated granules. According to the preparation method, easily-oxidized groups in lycopene are embedded in a molecule well of beta-CD for protection so that the stability of products in shelf life is improved; and since the enteric-soluble material is used for coating for further protection so as to prevent lycopene from being damaged in gastric acid and control the release of granules in an enteric canal so as to improve the bioavailability. In order to further improve the stability of SOD and directly conveying the SOD to small intestinal to be absorbed for improving the bioavailability, the molecule embedding is carried out on SOD by beta-cyclodextrin which is at least 50 times as much as SOD according to a grinding method, and then the bedded SOD is prepare into 40-mesh granules, and finally the granules are coated with the enteric-soluble coated premix auxiliary materials to obtain the enteric-soluble granules, so that the stability of the product in the shelf life can be improved, and the damage of the product in the gastric acid can be avoided.

The invention relates to the medicine technical field, specifically relates to an efonidipine hydrochloride-containing suspension and a solid preparation thereof, and a preparing method of the suspension and the solid preparation, and in particular, relates to the cefonidipine hydrochloride-containing suspension and the solid preparation thereof, and the method for preparing the preparation through a wet medium grinding process. The suspension includes a drug, a stabilizer, lauryl sodium sulfate, a pH regulator and purified water, and particularly includes the following components by the weight percentage: 11.4%-33.0% of the drug, 0.86%-4.13% of the stabilizer, 0.08%-0.81% of lauryl sodium sulfate, 0.5%-5.0% of the pH regulator, and the balance water. The suspension can be further made into a spray dried powder, enteric coated granules and the like. The prescription is fast to dissolve, and the preparing process is simple, and adapts to industrial production.

The invention provides an oxiracetam enteric-coated capsule. Oxiracetam in special crystallization form is used as an active component. A composite carrier containing polyoxyethylene PEO and hydroxypropyl methyl cellulose ( or polyvinylpyrrolidone) in the mass ratio of the polyoxyethylene PEO to the hydroxypropyl methyl cellulose being (1-3) to 1, is carefully selected, and the prepared oxiracetamenteric-coated preparation can reduce the dissolution rate of the active component in the stomach, and also has favorable slow control slow release properties and storage stability. The prepared oxiracetam enteric-coated granules are subjected to long-term stability test under the condition that the temperature is 25 DEG C+/-2 DEG C, and the relative humidity is 60%+/-10%, and after long-term experiment for 24 months, sample properties, content and related substances all conform to specification. The oxiracetam enteric-coated capsule is good in stability, and long in quality guarantee period.The preparation method is simple, and suitable for industrial production.

The invention provides a melbine/migltol hypoglycemic oral preparation composition and a preparation thereof. The weight ratio of the two main medicaments comprised in the composition is 2:3 to 200:1, preferably, 1:1 to 150:1. Except the main medicaments, the composition also can further comprises normal medicament auxiliary materials, such as an adhesive, a filling agent, a disintegrating agent, a lubricating agent, a flavoring agent, a wetting agent and a glidant. The prepared composition can be prepared into tablets, granules, capsules and sustained-release preparations by the common method, preferably, enteric-coated tablets, enteric-coated granules and enteric-coated capsules. The composition of the invention has the advantages of complementarity of action mechanisms of the main medicaments, multiple target points, good patient compliance and the like. The hypoglycemic oral preparation composition can be used for first-line treatment of type 2 diabetes, or can be used for second-line therapy under the condition that a melbine or sulfonylurea medicament cannot singly and effectively control the blood sugar.

The invention provides a pharmaceutical composition for treatment of senile dementia, wherein the pharmaceutical composition comprises levooxiracetam enteric-coated granules. The levooxiracetam enteric-coated granules take the combination of polyacrylic acid resin and cellulose acetate phthalate with a specific proportion as an enteric-coated coating material. The prepared levooxiracetam enteric-coated granules are released in intestinal juice, and the granules are spherical in appearance, have an angle of repose between 30 and 32 degrees, have the advantages of good fluidity, uniform granules, good content uniformity, and hard and heavy granules, have loading amount difference less than 2.5%, and have the dissolution rate higher than 99.0%. The preparation method is simple and suitable for industrialized production.

The invention belongs to the technical field of veterinary medicines, and particularly relates to a preparation method of Tylvalosin enteric coated granules. The preparation method comprises the following steps of (1) preparing Tylvalosin granules from: Tylvalosin, dextrin, orally-taken sugar, stevioside, ethyl maltol, a sausage casing material, a stuffing agent, a disintegrant and starch pulp; (2) performing material mixing: uniformly mixing the Tylvalosin with the dextrin, the orally-taken sugar, the stevioside, the ethyl maltol and the sausage casing material, performing crushing, performing screening to obtain mixed powder, adding an appropriate quantity of the solvent to the mixed powder, performing uniform mixing, adding the stuffing agent, the disintegrant and the starch pulp, and performing uniform mixing to prepare soft materials; and (3) performing granulation: making wet granule minipills from the prepared soft materials, and performing drying until the obtained Tylvalosin enteric coated granules are obtained. The prepared Tylvalosin enteric coated granules can be taken in groups, effective components of the Tylvalosin enteric coated granules are not destroyed by gastricacid and can safely reach intestines to be absorbed, and the feed conversion ratio can be notably increased.

The invention provides enteric-coated sustained-release granules for treatment of epilepsy. With dextrohydroxypyramide as an active ingredient, dextrohydroxypyramide is dispersed in a carrier materialof a mixture of hydroxypropyl methyl cellulose, methyl cellulose and xanthan gum in a specific proportion, and the dextrohydroxypyramide enteric-coated granules prepared by fluidized bed coating granulation are released in an artificial intestinal juice, have gentle and lasting drug release speed, do not generate sudden release phenomenon, achieve the effect of sustained and controlled release, and effectively guarantee the efficacy of drugs and pharmacy safety. The preparation method is simple, does not use materials with large toxicity in the preparation process, is economical and environmentally friendly, and is suitable for large-scale promotion.